Neuroendocrine Carcinoma Market Scope and Opportunities Analysis 2014 – 2020

A neuroendocrine tumor is a kind of tumor that begins in the hormone producing cells of the neuroendocrine system that is made up of the endocrine system and nervous system. Hormones producing neuroendocrine cells have a structure similar to neurons and produce hormones like endocrine cells. These cells are found throughout the body in organs such as intestines, kidneys, lungs and stomach and perform functions such as controlling the speed of food through gastrointestinal tract and air and blood flow through the lungs. Neuroendocrine tumor is a rare malignant disorder that accounts for nearly one percent of all malignant disorders. Neuroendocrine carcinomas account for nearly 60% of all neuroendocrine tumor cases and are characterized as their origin in different locations throughout the body including lungs, gastrointestinal tract and brain. Some common symptoms associated with neuroendocrine carcinoma are hyperglycemia, hypoglycemia, weight loss, loss of appetite, headache, anxiety, gastric ulcer, unusual bleeding, jaundice, diarrhea, fever and persistent in specific area.

Report Overview @ https://www.transparencymarketresearch.com/neuroendocrine-carcinoma-market.html

The treatment options for neuroendocrine carcinoma include surgery, radiation therapy and chemotherapy. Chemotherapy involves the use of drugs to kill cancerous cells by inhibiting the cells ability to grow and divide. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some drugs that are used to treat neuroendocrine carcinomas. Continuous efforts by major pharmaceuticals in order to develop targeted therapy have been contributing in the growth of neuroendocrine carcinomas market. Everolimus (Afinitor) and sunitinib (Sutent) are two major targeted drugs that are being used for treating neuroendocrine carcinomas. Afinitor was introduced by Novartis AG in 2009 for the treatment of advanced renal cell carcinoma. This drug is useful when sunitinib or sorafenib fail to treat the renal cell carcinoma. Sutent is a brand developed by Pfizer Ltd. and is used to treat advanced renal cell carcinoma and gastrointestinal stromal tumor. F. Hoffmann-La Roche Ltd., BioSynthema, Inc., Genentech Inc. and Callisto Pharmaceuticals Pvt. Ltd. are some major companies that are striving to develop drugs for treating various neuroendocrine carcinomas. Avastin, Atiprimod and Lutathera are among other molecules that are currently being studied for their therapeutic efficacy in the treatment of neuroendocrine carcinomas.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2970

Geographically, the market for neuroendocrine carcinoma has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). United States and Canada are the two major markets in North America region. North America represented the largest market for neuroendocrine carcinoma in 2013, with a largest market share in terms of revenue (USD Million). According to sources from Cancer.Net, nearly 8,000 people are diagnosed with neuroendocrine tumors every year in the United States. Many of the key players operating in this market space are based out of U.S and thus consider North America as their primary market for product launch and investment. Also, the well established healthcare infrastructure and reimbursement scenario are among the major factors responsible for North America’s leading position in neuroendocrine carcinoma market. Europe accounted for the second largest market in 2013, followed by Asia Pacific and Rest of the World (RoW). Growing incidence of neuroendocrine carcinoma in Asia Pacific along with the improving economic scenario is likely to play a key role in driving the market growth in the region.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2970

F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Ltd., Eli Lilly & Company, Amgen, Inc., Ispen SA, Callisto Pharmaceuticals Pvt. Ltd., Bristol-Myers Squibb, Teva Pharmaceuticals, Ltd. and Biosynthema, Inc. are among others operating in the Neuroendocrine carcinoma market.

DNA Vaccines Market Competitive Landscape Analysis with Forecast by 2019

Global DNA Vaccines Market: Overview

The global DNA vaccines market is expected to obtain a boost in growth due to demand for effective and low cost vaccines. The market could benefit from increasing infectious diseases, vulnerability of the population, and increase in the number of resistant pathogens. These vaccines have long lasting results and are proven effective over the traditional methods. These factors are likely to boost the market in the coming years.

Report Overview @ https://www.transparencymarketresearch.com/dna-vaccines-market.html

The global DNA vaccines market is segmented based on end user, application, technology, and type. Based on type, market is further segmented into animal DNA vaccines and human DNA vaccines. Based on technology, the DNA vaccine market is further segmented into DNA delivery technology and DNA vaccine technology. On the basis of applications, the market is segmented into human diseases i.e., allergies, infectious disease, oncology, and others; and veterinary diseases such as Equine West Nile Virus, Leishmaniasis, Canine Melanom, and others. Based on end user type, the market is segmented in research application, animal health, and human health.

This report provides an insight of the global DNA vaccine market with large focus on its significant dynamics. It provides information on important and critical trends and opportunities as well as the market restrains. It also covers the vendor landscape and how the growth of market will shape in the foreseeable future.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1584

Global DNA Vaccine Market: Trends and Opportunities

The need for vaccines that overcome the unsought properties of conventional vaccines will boost the market for DNA vaccine. These vaccines provide low risk of infections, stability at room temperature, and easy transportation. The demand for DNA vaccines is expected to grow rapidly due to its properties of reducing risk of infections as compared to conventional vaccines and improvised stability. The ease of large scale manufacturing compared to low storage requirement and traditional approach are predicted to boost the market. The increase in death due to unavailability of effective treatment for infectious diseases according to World Health Organization has led to demand for DNA vaccines all around the globe.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1584

The rapid development in field of DNA synthesis, immunology, and molecular biology has led to significant rise in the market. Increase in microbial resistance to antibiotics and antimicrobials and inefficient drug therapies have led to the increased demand. These vaccines will provide eradication of diseases such as HIV, hepatitis, cancer, and other. These vaccines are highly recommended for travelers as they are at an exposure to various diseases thus need of increased selective DNA vaccines for different geographical regions are accelerating the demand for DNA vaccines.

Global DNA Vaccine Market: Geographical Analysis

North America is leading the global DNA vaccine market due to increase in patient population pool, growth of government investments, and rise in geriatric population. The government is also involved in development of efficient healthcare facilities and research & development activities. This region dominates the market amongst all other regions.

The increase in diseases in countries such as U.S. and Canada is also driving the demand of vaccination technology. The morality rate due to infectious and chronic diseases has increased in U.S. and is increasing each year. It has made the government involved in agencies such as national institute of allergy, national institute of health, and others for development of DNA based vaccines. It has promoted the growth of market in the U.S. The rise in awareness regarding the benefits among people is likely to drive the market. The major contribution to the market will be from U.S. and Canada due to predominance of irresistible and incessant sickness in animals as well as humans in this region.

Global DNA Vaccine Market: Companies Mentioned

Some of the prominent companies operating this market are Tekmira Pharmaceuticals, Sanofi, Vical, Astellas Pharma, Dendreon Corporation, Merck & Co., Invio Biomedical, and Novartis Animal Health.

Antisense and RNAi Therapeutics Market Growth Opportunities & Technology Developments by 2023

Global Antisense and RNAi Therapeutics Market: Overview

The rising incidence of coronary artery diseases, cardiac ailments, and neurodegenerative and infectious diseases has led to the demand for antisense and RNai therapeutics. The market exhibits a strong pipeline of product and is looking forward to introduce several advancements in the RNAi drug delivery technology. These factors will act as high growth rendering drivers in the coming years.

Report Overview @ https://www.transparencymarketresearch.com/antisense-rnai-therapeutics-market.html

The global antisense and RNAi therapeutics market is still at a nascent stage, however, will product approvals on cards, the market is forecast to report strong growth between 2015 and 2023. Market players are expecting lucrative prospects as collaborations between RNA licensing therapeutic developers and pharmaceutical giants gain pace.

The report provides a comprehensive analysis of the global antisense and RNAi therapeutics market covering present product portfolio and those in pipeline. Factors influencing the market’s trajectory over the forecast period are studied in detail. Information included in the report is obtained via trusted industrial sources and substantiated using decisive data. Information comprised in the report is thus intended to help stakeholders gain a better perspective of the global antisense and RNAi therapeutics market.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4949

Global Antisense and RNAi Therapeutics Market: Trends and Opportunities

Besides collaborations between therapeutic developments and pharmaceutical companies, alliances are taking place between operating entities and outsourcing partners. These alliances have allowed operating entities outsource research and licensing activities to third-party partners while focusing on their core competencies. These recent trends, as per industry veterans, hold strong growth potential for the overall market.

Moreover, the discovery of ribonucleic acid silencing has paved avenues for treatments, which are developed using interference mechanism of RNA. However, the market is yet to pick desired pace, as complexities with regards to delivering target molecules to target organs continue to haunt scientists and drug developers. Nevertheless, with the advent of novel nano-technology oriented techniques, which exhibited higher efficacy in target delivery, has enabled the industry exhibit positive trajectory. Also with the implementation of favorable government initiatives and as a result of external funding, the global antisense and RNAi therapeutics market will exhibit strong growth in the coming years.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=4949

Global Antisense and RNAi Therapeutics Market: Regional Outlook

The global antisense and RNAi therapeutics market can be broadly classified under North America, Latin America, Europe, the Middle East & Africa, and Asia Pacific based on region. Of these, North America has showcased the most lucrative opportunities in the past and has thus contributed a considerable share to the overall industry. The region boasts a rising number clinical trials and government policies therein support the process of initiation for developing antisense therapeutics. Besides this, a large number of clinical laboratories are engaged in research and development activities in the field, which has warranted significant growth to the North America market in the coming years. It is important to note here, that clinical laboratories in North America also contribute to revenue generation via product and platform licensing. The potential commercialization of a few candidates under research and development will help the antisense and RNAi therapeutics market to pick up pace in North America in the near future.

However, in the period post commercialization of these therapies, opportunities in Asia Pacific are expected to get more lucrative, exhibiting a higher growth rate. The rising government spending toward research and development in topical, besides other forms of siRNA delivery techniques is a strong factor aiding the market’s trajectory in Asia Pacific.

Global Antisense and RNAi Therapeutics Market: Vendor Landscape

Isis Pharmaceuticals, Alnylam Pharmaceuticals, Silence Therapeutics, Antisense Therapeutics, Santaris, and miRagen Therapeutics are some of the leading players in the global antisense and RNAi therapeutics market. To gain a stronger foothold, these companies are majorly focusing on strategic collaborations and licensing deals.

Biodefense Market: Global Segments, Top Key Players, Size and Recent Trends by Forecast to 2025

Global Biodefense Market: Overview

Biodefense has been advancing, particularly in the U.S., subsequent to the 2001 anthrax attack. The use of biological warfare can be traced back to 1346 A.D. when plaque afflicted human corpses were hurled over the besieged walls of Caffa. Presently, the use of biological warfare is banned following a United Nations convention signed in 1972. However, the absence of verification protocol has not been sufficient to prevent countries from developing biological warfare. Biological warfare has also become the weapons of choice for terrorist organizations. To combat this, the development of biodefense is an active research field.

Report Overview @ https://www.transparencymarketresearch.com/biodefense-market.html

The research report analyzes the global biodefense market on the basis of market forces, current market trends, and major geographies. The report is an in-depth analysis of industry growth drivers, challenges, and opportunities of the market for the forecast period. It includes an analysis of recent technological developments in the market.


Using standard analytical tools such as SWOT analysis, the report presents the strengths, weakness, opportunities, and threats of the market until the end of the forecast period in 2023. The report also covers an analysis impact of macro and micro factors on the growth of the market, which is essential for existing market players as well as new entities that are interested in participating in the market. Thus, the report analysis helps in formulating informed business decisions by receiving detailed insights into the development of the key market segments.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5369
Global Biodefense Market: Drivers and Restraints
The global biodefense market is displaying admirable growth due to the increasing importance for disease surveillance mission to combat bioterrorism. The outbreak of anthrax subsequent to September 11, 2001, attack has raised vigilance among government bodies for improving public health preparedness and to improve the response time in the event of a disaster. The funding for preparedness of bioterrorism has augmented the capabilities of Public Health Services to enhance its surveillance activities, resulting in effective monitoring of community health. The increasing focus of Public Health Services for the development of tests and procedures to identify biothreat agents is also driving the biodefense market. The recent Ebola outbreak and nuclear crisis in Japan are anticipated to have a positive impact on the growth of the biodefense market.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=5369

Global Biodefense Market: Regional Outlook

The global biodefense market is divided into the regional segments of North America, Europe, Asia Pacific, and the Middle East and Latin America. North America is the largest market for biodefense due to enhanced lab capabilities and improved infrastructure for raising alarm for the threat to health. Europe is the second largest market for biodefense. Asia Pacific is expected to emerge as a significant market for biodefense due to the increasing adoption of precise analytical instruments and rapid advancement of the biotechnology industry. Other regions such as the Middle East and Latin America are anticipated to be significant regions for biodefense due to the expanding portfolio of leading biotechnology players in these regions.

Major Companies Mentioned in Report

Some of the leading companies operating in the global biodefense market are Alnylam Pharmaceuticals, Dynavax Technologies Inc., Emergent BioSolutions, SIGA Technologies, Acambis plc, Evogen Inc., Human Genome Sciences, and PharmAthene Inc.

Home Medical Equipment Rental Market Industry Demands, Top Key Players, Industry Analysis & Forecast By 2023

Home Medical Equipment Rental Market: Overview

Home medical equipment comprises of a wide range of devices intended for use in home or other non-clinical facilities. This broad spectrum category includes medical electronic equipment such as digital blood-glucose meters, blood pressure monitoring devices, respiratory assist devices, and home infusion therapy. It also includes products such as artificial limbs, nebulizers, seat lifts, walkers, hospital beds and other prosthetic devices as the delivery of healthcare services shifts from clinical settings to the home devices.

Report Overview @ https://www.transparencymarketresearch.com/home-medical-equipment-rental-market.html

Home Medical Equipment Rental Market: Trends and Drivers

Home medical equipment market is expected to grow tremendously in the coming years, as the delivery of healthcare services will see an evident shift from clinical settings (such as hospitals and private nursing care) to the home. The overall home medical equipment rental market influenced by several market drivers such as more people with private insurance, aging population across the world, increased life expectancy, consistent rise in geriatric population, escalating national healthcare spending and increased incidence of chronic disorders across the globe.

External factors like diligent insurance reimbursement policies, healthcare providers are consistently focused on lowering costs of healthcare, in part by shifting limited resources to acute cases, and relying on patients and their families to take on a more active role in their own health care. However, it also presents unique challenges and issues like potential safety checklists to both, patients and caregivers, operating environment and skills, supplying equipment, regulatory restrains and industry standards.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11801

Home Medical Equipment Rental Market: Segmentation

The home medical equipment rental market can be analyzed on the basis of different market scenarios such as acceptability and feasibility for non-technical consumer like patient himself as well as acceptance in several geographical region of the world.

By geography, the market can be segmented in North America, Europe, Asia pacific and rest of world (ROW). North America and Asia Pacific promise to be the most lucrative market for the home medical equipment rental due to the budget constraints faced by the hospital, increasing incidences of large number of chronic disorders and increasing number of aging patients. Europe also promises impressive growth in this market because long-lasting chronic conditions and disabilities.

According to a United Nations report, the rise in the population aged 80 years or above is moving at a faster pace in the less developed regions than in the more developed regions. 23 million persons aged 80 years or over were living in China in 2013. The USA had about 12 million, followed by India and Japan, which had 10 million and 9 million, respectively. Apart from this increase expenditure in healthcare is also responsible for the shifting paradigm.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=11801

Home Medical Equipment Rental Market: Opportunities

According to The Centers for Medicare and Medicaid Services (CMS), Spending growth for freestanding home health care agencies accelerated in 2012, increasing 5.1 percent to $77.8 billion following growth of 4.1 percent in 2011.The CMS also estimates that spending on healthcare services will grow to $3.4 trillion by 2015, nearly 18% of GDP. Over the time frame of 2015-2021, health spending is expected to grow at the rate of 6.2% annually. It reflects the net result of the aging of the population, Affordable Care Act, and generally improving socio-economic conditions.

Home healthcare equipment rental market varies considerably in the past few years. An industry report on the global market for home medical equipment estimates the total expenditure at $40.5 billion in 2009. This is about 1-2% of the total expenditures on healthcare services in the United States. The report also estimated growth rate around 7.4% between now and 2016. Extrapolation of this estimation can be a good indicator of health equipment rental market.

Home Medical Equipment Rental Market: Key Players

The key players in this market are Agfa Finance Corp., Access Equipment Leasing, De Lage Landen International B.V., Apria Healthcare Group (USA), Hill-Rom Holdings, Inc., GE Healthcare Financial Services, Siemens Financial Services, National Technology Leasing Corp., Prudential Leasing, Inc., Oak Leasing Ltd, Rotech Healthcare Inc., and Stryker Corporation.

Acute Myeloid Leukemia (AML) Therapeutics Market: Review with Forecast Research Report 2015 - 2025

Global Biodefense Market: Overview

Biodefense has been advancing, particularly in the U.S., subsequent to the 2001 anthrax attack. The use of biological warfare can be traced back to 1346 A.D. when plaque afflicted human corpses were hurled over the besieged walls of Caffa. Presently, the use of biological warfare is banned following a United Nations convention signed in 1972. However, the absence of verification protocol has not been sufficient to prevent countries from developing biological warfare. Biological warfare has also become the weapons of choice for terrorist organizations. To combat this, the development of biodefense is an active research field.

Report Overview @ https://www.transparencymarketresearch.com/biodefense-market.html

The research report analyzes the global biodefense market on the basis of market forces, current market trends, and major geographies. The report is an in-depth analysis of industry growth drivers, challenges, and opportunities of the market for the forecast period. It includes an analysis of recent technological developments in the market.

Using standard analytical tools such as SWOT analysis, the report presents the strengths, weakness, opportunities, and threats of the market until the end of the forecast period in 2023. The report also covers an analysis impact of macro and micro factors on the growth of the market, which is essential for existing market players as well as new entities that are interested in participating in the market. Thus, the report analysis helps in formulating informed business decisions by receiving detailed insights into the development of the key market segments.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5369

Global Biodefense Market: Drivers and Restraints

The global biodefense market is displaying admirable growth due to the increasing importance for disease surveillance mission to combat bioterrorism. The outbreak of anthrax subsequent to September 11, 2001, attack has raised vigilance among government bodies for improving public health preparedness and to improve the response time in the event of a disaster. The funding for preparedness of bioterrorism has augmented the capabilities of Public Health Services to enhance its surveillance activities, resulting in effective monitoring of community health. The increasing focus of Public Health Services for the development of tests and procedures to identify biothreat agents is also driving the biodefense market. The recent Ebola outbreak and nuclear crisis in Japan are anticipated to have a positive impact on the growth of the biodefense market.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=5369

Global Biodefense Market: Regional Outlook

The global biodefense market is divided into the regional segments of North America, Europe, Asia Pacific, and the Middle East and Latin America. North America is the largest market for biodefense due to enhanced lab capabilities and improved infrastructure for raising alarm for the threat to health. Europe is the second largest market for biodefense. Asia Pacific is expected to emerge as a significant market for biodefense due to the increasing adoption of precise analytical instruments and rapid advancement of the biotechnology industry. Other regions such as the Middle East and Latin America are anticipated to be significant regions for biodefense due to the expanding portfolio of leading biotechnology players in these regions.

Major Companies Mentioned in Report

Some of the leading companies operating in the global biodefense market are Alnylam Pharmaceuticals, Dynavax Technologies Inc., Emergent BioSolutions, SIGA Technologies, Acambis plc, Evogen Inc., Human Genome Sciences, and PharmAthene Inc.

Gastrointestinal Endoscopic Devices Market: Growth Analysis, Trends and Scope till 2019

Devices used to inspect the internal lining of the gastrointestinal tract are termed as gastrointestinal endoscopic devices. Gastrointestinal (GI) tract includes small intestine, large intestine, duodenum, colon, stomach, cecum and rectum. Any infection or abnormalities in function of this GI tract is detected for using gastrointestinal endoscopic devices. These devices are helpful in detecting the cause of abdominal bleeding, vomiting, persistent pain, inflammation and tumor affecting the esophagus, duodenum and stomach. In addition they also help in treating these GI diseases. Various GI diseases include ulcer, gastroesophageal reflux disease, hemorrhoids, colon cancer, diverticulitis, bowel syndrome and Crohn’s disease.

Report Overview @ https://www.transparencymarketresearch.com/gastrointestinal-endoscopic-devices.html

Gastrointestinal endoscopic devices include thin flexible tube, light attached to thin flexible tube and a visualizer. Other components of this device are viewing sheath, power source, rheostat, lasers, insufflators, battery box, bulbs, fiberoptic lighting, hand instruments, electrosurgical and radiofrequency instruments. The process of detecting GI tract abnormalities through GI endoscopic devices is termed as gastrointestinal endoscopy. This process starts with anesthetizing the patient and then putting thin wire in the GI tract through mouth. The internal structure image is displayed on the visualizer. This image helps the physician to detect and treat the GI infections.

Gastrointestinal endoscopic devices are further segmented as endoscopic retrograde cholangiopancreatography devices (ERCP), hemostatis devices, capsule endoscopy, biopsy devices and GI videoscopes. GI videoscopes include video gastroscopes, video duodenoscopes, video colonoscopies, video ultrasound endoscopes, video enteroscope and video sigmoidoscope. Other GI endoscopic devices include stents, enteral feeding devices, esophageal dilation balloons, polypectomy snares, and anti-reflux devices.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1406

Changing lifestyle has changed the diet pattern. The new diet has reduced the intake of various healthy foods which increases the incidence of digestive tract problems. In addition, increase in GI diseases has also triggered the growth of this market. Recently in year 2011, 1 million of the total worldwide population has been detected with colon and rectum cancer. Weight management treatment has also contributed in its growth since this therapy includes gastric banding and bypass surgery. Global increase in disposable income has also boosted the growth of this market. Despite all the advantages, the growth of this market would be hampered due to lack of sufficient reimbursement policies and reduced government funding in various nations such as Europe and U.S. respectively. In addition, high costs and delayed approval process would also hinder the growth of this market.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1406

Some of the major market players in this industry are Covidien Ltd., Boston Scientific Corporation, Conmed Corporation, Johnson & Johnson Ltd., Fujinon Ltd., Stryker Corporation and other significant players.